<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aspire Biopharma, Inc. — News on 6ix</title>
<link>https://6ix.com/company/aspire-biopharma-inc</link>
<description>Latest news and press releases for Aspire Biopharma, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aspire-biopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835486a78dffbe2df0e3d08.webp</url>
<title>Aspire Biopharma, Inc.</title>
<link>https://6ix.com/company/aspire-biopharma-inc</link>
</image>
<item>
<title>Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-closing-of-second-and-final-tranche-of-dollar21-million-private-placement-by-select-investors-secures-commitment-letter-for-dollar225m-credit-facility-to-fund-the-dcs-acquisition</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-closing-of-second-and-final-tranche-of-dollar21-million-private-placement-by-select-investors-secures-commitment-letter-for-dollar225m-credit-facility-to-fund-the-dcs-acquisition</guid>
<pubDate>Mon, 20 Apr 2026 12:30:00 GMT</pubDate>
<description>Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS) LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected ...</description>
</item>
<item>
<title>Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bombtm-caffeine-companys-brand-ambassador-ashley-paulson-to-attempt-fastest-100-mile-treadmill-run-at-2026-boston-marathon-expo</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bombtm-caffeine-companys-brand-ambassador-ashley-paulson-to-attempt-fastest-100-mile-treadmill-run-at-2026-boston-marathon-expo</guid>
<pubDate>Fri, 17 Apr 2026 12:00:00 GMT</pubDate>
<description>Elite Ultra-Marathoner targets her second World Record in two months following historic Ultra Jackpot 100 Win ESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned ...</description>
</item>
<item>
<title>Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-has-entered-into-a-letter-of-intent-to-acquire-a-leading-global-automotive-supplier-with-a-100-year-history-and-dollar200m-in-2025-revenue</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-has-entered-into-a-letter-of-intent-to-acquire-a-leading-global-automotive-supplier-with-a-100-year-history-and-dollar200m-in-2025-revenue</guid>
<pubDate>Thu, 16 Apr 2026 12:30:00 GMT</pubDate>
<description>ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered ...</description>
</item>
<item>
<title>Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bomb-caffeine-company-partners-with-interwest-brokerage-to-accelerate-retail-expansion</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bomb-caffeine-company-partners-with-interwest-brokerage-to-accelerate-retail-expansion</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>Interwest to Drive Regional Growth for BUZZ BOMB™ Across Major Grocery and Convenience Channels ESTERO, FL / ACCESS Newswire / April 15, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, ...</description>
</item>
<item>
<title>Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-subsidiary-announces-agreement-with-trulife-distribution-to-drive-national-retail-expansion</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-subsidiary-announces-agreement-with-trulife-distribution-to-drive-national-retail-expansion</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Agreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels ESTERO, FL / ACCESS Newswire / March 19, 2026 /</description>
</item>
<item>
<title>Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-subsidiary-buzz-bomb-caffeine-company-appoints-john-choe-as-western-sales-director</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-subsidiary-buzz-bomb-caffeine-company-appoints-john-choe-as-western-sales-director</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the ...</description>
</item>
<item>
<title>Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-subsidiary-to-feature-buzz-bombtm-at-the-health-and-fitness-show-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-subsidiary-to-feature-buzz-bombtm-at-the-health-and-fitness-show-2026-1</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health & Fitness (HFA) Show, scheduled for March 16-18 ...</description>
</item>
<item>
<title>Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bombtm-disrupts-energy-category-with-new-convenience-store-pack-1</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bombtm-disrupts-energy-category-with-new-convenience-store-pack-1</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Convenient Size at the Convenience Store ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today</description>
</item>
<item>
<title>Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-partners-with-microsize-to-develop-rapid-delivery-sublingual-powder-formulation-of-alprazolam-for-faster-anxiety-relief-1</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-partners-with-microsize-to-develop-rapid-delivery-sublingual-powder-formulation-of-alprazolam-for-faster-anxiety-relief-1</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026. Alprazolam remains a top ...</description>
</item>
<item>
<title>Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief </title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-partners-with-microsize-to-develop-rapid-delivery-sublingual-powder-formulation-of-alprazolam-for-faster-anxiety-relief</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-partners-with-microsize-to-develop-rapid-delivery-sublingual-powder-formulation-of-alprazolam-for-faster-anxiety-relief</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.Phase 1 clinical trial of</description>
</item>
<item>
<title>Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bombtm-caffeine-company-achieves-record-social-media-growth-and-sales-surge-following-world-record-marathon-sponsorship</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bombtm-caffeine-company-achieves-record-social-media-growth-and-sales-surge-following-world-record-marathon-sponsorship</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival. ESTERO, FL / ACCESS Newswire / February 25, 2026 / Aspire Biopharma ...</description>
</item>
<item>
<title>Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-regains-full-compliance-with-nasdaq-listing-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-regains-full-compliance-with-nasdaq-listing-requirements</guid>
<pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
<description>Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed Aspire maintains listing on the Nasdaq ESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), ...</description>
</item>
<item>
<title>Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bomb-caffeine-company-names-chicexecs-as-public-relations-agency-of-record</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharmas-buzz-bomb-caffeine-company-names-chicexecs-as-public-relations-agency-of-record</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement ...</description>
</item>
<item>
<title>Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-files-provisional-patent-133000677</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-files-provisional-patent-133000677</guid>
<pubDate>Tue, 17 Feb 2026 13:30:00 GMT</pubDate>
<description>New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®. Meclizine was the top-prescribed antiemetic/antivertigo agent in 2023, with approximately ...</description>
</item>
<item>
<title>Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-appointment-member-130000376</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-appointment-member-130000376</guid>
<pubDate>Fri, 13 Feb 2026 13:00:00 GMT</pubDate>
<description>New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform ESTERO, FL / ACCESS Newswire / February 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" ...</description>
</item>
<item>
<title>Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-files-provisional-patent-130000144</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-files-provisional-patent-130000144</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran®, was the 53rd most commonly prescribed medication in the U.S. in 2023 Global ondansetron ...</description>
</item>
<item>
<title>Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) </title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-files-provisional-patent-application-for-a-fast-acting-sublingual-powder-formulation-of-ondansetron-generic-zofranr</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-files-provisional-patent-application-for-a-fast-acting-sublingual-powder-formulation-of-ondansetron-generic-zofranr</guid>
<pubDate>Thu, 12 Feb 2026 05:00:00 GMT</pubDate>
<description>New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, currently sold under the brand name</description>
</item>
<item>
<title>Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-21-million-124500380</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-21-million-124500380</guid>
<pubDate>Wed, 11 Feb 2026 12:45:00 GMT</pubDate>
<description>ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it ...</description>
</item>
<item>
<title>Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements </title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-dollar21-million-private-placement-by-select-investors-strengthening-balance-sheet-capital-position-and-fortifying-shareholder-equity-to-meet-nasdaq-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-announces-dollar21-million-private-placement-by-select-investors-strengthening-balance-sheet-capital-position-and-fortifying-shareholder-equity-to-meet-nasdaq-requirements</guid>
<pubDate>Wed, 11 Feb 2026 05:00:00 GMT</pubDate>
<description>ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company</description>
</item>
<item>
<title>Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-regains-compliance-nasdaq-130000396</link>
<guid isPermaLink="true">https://6ix.com/company/aspire-biopharma-inc/news/aspire-biopharma-regains-compliance-nasdaq-130000396</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical ...</description>
</item>
</channel>
</rss>